Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Items 401–500 of 765
Gene Therapy for Coagulation Disorders
Swystun, L. L., & Lillicrap, D. (2016) · Circulation Research · doi:10.1161/circresaha.115.307015 · Cited by 26
Hemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 25
Exploiting Natural Diversity of AAV for the Design of Vectors with Novel Properties
Gao, G., Li, Z., & Danos, O. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_4 · Cited by 28
Hai, B., Yan, X., Voutetakis, A., Zheng, C., Cotrim, A. P., Shan, Z., Ding, G., Zhang, C., Xu, J., Goldsmith, C. M., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1319 · Cited by 24
“[28] CTL-mediated responses occurred at vector doses >2 × 1012 pu/kg, whereas,”
BackgroundInfluentialKomatsu, K., Shibata, T., Shimada, A., Ideno, H., Nakashima, K., Tabata, Y., & Nifuji, A. (2016) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2016.1139486 · Cited by 24
“[18] Another viral vector, the adeno-associated virus vector has been used as a gene therapy vector in patients with hemophilia B; however, severe host immune responses were observed in patients treated with this vector.[19,20] Gene delivery by plasmid nonviral DNA is safer but less efficient than that by viral vector…”
BackgroundVandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer
Chen, K., Ernst, P., Sarkar, A., Kim, S., Si, Y., Varadkar, T., Ringel, M. D., Liu, M., & Zhou, L. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0984 · Cited by 28
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Westhaus, A., Cabanes‐Creus, M., Dilworth, K. L., Zhu, E., Gómez, D. S., Navarro, R. G., Amaya, A. K., Scott, S., Kwiatek, M., McCorkindale, A. L., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.188 · Cited by 25
Esposito, F., Dell’Aquila, F., Rhiel, M., Auricchio, S., Chmielewski, K. O., Andrieux, G., Ferla, R., Horrach, P. S., Padmanabhan, A., Cunto, R. D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101619 · Cited by 32
Noviello, M., Tedesco, F. S., Bondanza, A., Tonlorenzi, R., Carbone, M. R., Gerli, M., Marktel, S., Napolitano, S., Cicalese, M. P., Ciceri, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.62 · Cited by 25
Suda, T., & Liu, D. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.002 · Cited by 24
Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases
Berns, K. I., & Srivastava, A. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.005 · Cited by 23
Enhanced T Cell Function in a Mouse Model of Human Glycosylation
Buchlis, G., Odorizzi, P. M., Soto, P. C., Pearce, O. M. T., Hui, D. J., Jordan, M. S., Varki, A. P., Wherry, E. J., & High, K. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202905 · Cited by 24
Self-citationRagni, M. V., Wu, W., Liang, X., Hsieh, C., Cortese‐Hassett, A., & Lü, L. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.02.011 · Cited by 23
“Future studies will be needed to address these issues as well as to determine if findings in mice apply to humans, given the immunologic differences anticipated in scale up from mice to men, as recognized in hemophilia gene transfer [29].”
BackgroundSelf-citationGernoux, G., Guilbaud, M., Dubreil, L., Larcher, T., Babarit, C., Ledevin, M., Jaulin, N., Planel, P., Moullier, P., & Adjali, O. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.070 · Cited by 23
“10,12 Thus, much more remains to be done to better understand the impact of AAV-based liver transduction on the immune system.”
Recombinant adeno-associated virus vectors in the treatment of rare diseases
Hastie, E. L., & Samulski, R. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1039511 · Cited by 25
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
Fuchs, S. P., Martinez-Navío, J. M., Gao, G., & Desrosiers, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158009 · Cited by 23
“If the administered AAV vector dose is too high, anti-AAV capsid immune responses can negatively influence the outcome of AAV-mediated gene transfer leading to a loss of efficacy [10,41,48,49].”
BackgroundRose, M. D., Gao, K., Cortez-Toledo, E., Agu, E., Hyllen, A. A., Conroy, K. L., Pan, G., Nolta, J. A., Wang, A., & Zhou, P. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0261 · Cited by 22
“Repeated application of AAV therapy is prohibited because administration again could induce a deleterious immune response to the viral capsids.(4,5) Cell therapy is actively being studied as a potential alternative for treatment of HA.”
BackgroundEngineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies
Ito, M., Takino, N., Nomura, T., Kan, A., & Muramatsu, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88614-9 · Cited by 23
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.375.3797885 · Cited by 23
Self-citationTalla, V., Porciatti, V., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., & Guy, J. R. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14688 · Cited by 24
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 25
Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing
Clarissa, E. M., Karmacharya, M., Choi, H., Kumar, S., & Cho, Y. (2025) · Small · doi:10.1002/smll.202409353 · Cited by 30
Lorek, J. K., Isaksson, M., & Nilsson, B. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28932 · Cited by 24
“…is dependent on several factors such as cell production system, serotype, batch variations, plasmid design, and transfection efficiency (Flotte 2017; Q. Fu, Lee, et al. 2023; Nguyen et al. 2021; G. Qu et al. 2007; Schnödt and Büning 2017 Q. Li et al. 2008; Manno et al. 2006; Mingozzi et al. 2007).”
Adeno‐Associated Virus Vector–Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver
Junge, N., Mingozzi, F., Ott, M., & Baumann, U. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000703 · Cited by 23
“org can result in loss of transgene expression (39), whereas animals do not (40).”
BackgroundSelf-citationLing, C., Li, B., Ma, W., & Srivastava, A. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.054 · Cited by 22
Viral vector-mediated transgenic cell therapy in regenerative medicine: safety of the process
Liu, Y., & Wang, D. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.995086 · Cited by 26
“Upon AAV gene transfer to the liver, observed tissue damage was most likely mediated by a CD8 T-cell response against the AAV capsid, relating that innate immune recognition through TLR9 signaling might be involved [17-19].”
BackgroundGenetic manipulation of brain endothelial cells in vivo
Assmann, J. C., Körbelin, J., & Schwaninger, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.006 · Cited by 23
Bioanalysis of Adeno-Associated Virus Gene Therapy Therapeutics: Regulatory Expectations
Gorovits, B., Marshall, J.-C. A., Smith, J., Whiteley, L. O., & Neubert, H. (2019) · Bioanalysis · doi:10.4155/bio-2019-0135 · Cited by 22
Selot, R., Arumugam, S., Mary, B., Cheemadan, S., & Jayandharan, G. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00441 · Cited by 20
“This will need AAV vectors that express therapeutic levels of the transgene at low vector doses to circumvent dose dependent immunotoxicity (Manno et al., 2006; Mingozzi et al., 2007).”
BackgroundChen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
Optimizing liver health before and after gene therapy for hemophilia A
Ragni, M. V., Mead, H., de Jong, Y. P., Kaczmarek, R., Leavitt, A. D., Long, B. R., Nugent, D. J., Sabatino, D. E., Fong, S., von Drygalski, A., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013059 · Cited by 20
“38,39 However, more recent trials using similar assays, including trials in HA gene therapy, have not fully recapitulated these fi ndings.”
BackgroundSelf-citationCorydon, T. J., & Bek, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101323 · Cited by 20
Preclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
Self-citationPalaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.004 · Cited by 19
AAV Provides an Alternative for Gene Therapy of the Peripheral Sensory Nervous System
Beutler, A. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.41 · Cited by 19
Lam, A. K., Mulcrone, P. L., Frabutt, D. A., Zhang, J., Chrzanowski, M., Arisa, S., Muñoz-Melero, M., Li, X., Biswas, M., Markusic, D. M., et al. (2023) · Advances in Cell and Gene Therapy · doi:10.1155/2023/2339702 · Cited by 21
“In other cases, they were undesirable as they could elicit liver toxicity due to activation of CD8 + T cells and TLR2 [21 – 23].”
BackgroundViral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 24
Fargnoli, A. S., Mu, A., Katz, M. G., Williams, R. D., Margulies, K. B., Weiner, D. B., Yang, S. M., & Bridges, C. R. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-171 · Cited by 20
Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, D. M., Nichols, T. C., Merricks, E. P., Palaschak, B., Zolotukhin, I., Marsic, D., Zolotukhin, S., Srivastava, A., & Herzog, R. W. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1200-1 · Cited by 19
“Capsid-specific cytotoxic T lymphocytes can target AAV transduced hepatocytes, resulting in loss of expression and toxicity [10, 11].”
Chaanine, A. H., Kalman, J., & Hajjar, R. J. (2010) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2010.09.009 · Cited by 21
Carlon, M. S., Vidović, D., Dooley, J., da Cunha, M. M., Maris, M., Lampi, Y., Toelen, J., Van den Haute, C., Baekelandt, V., Deprest, J., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.196 · Cited by 19
“In clinical trials using rAAV for patients with hemophilia B, the stability of gene expression was hampered by a capsid-specific cytotoxic T cell response (Mingozzi et al., 2007; Nathwani et al., 2011), which was not predicted by preclinical animal studies (Li et al.”
BackgroundEgorova, T. V., Starikova, A. V., & Polikarpova, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111492 · Cited by 20
“T-cell activation and associated hepatotoxicity have been observed in patients in clinical trials involving systemic administration of AAV-based drugs [7].”
Emerging and potential use of CRISPR in human liver disease
Adlat, S., Vázquez-Salgado, A. M., Lee, M., Yin, D., & Wangensteen, K. J. (2025) · Hepatology · doi:10.1097/hep.0000000000000578 · Cited by 21
Ortved, K. F., Wagner, B., Calcedo, R., Wilson, J. M., Schaefer, D. M. W., & Nixon, A. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.050 · Cited by 19
“13,14 19–22 Cytotoxic CD8 + T cells that recognize capsid proteins loaded into MHC-I would be of particular concern as they would be able to eliminate transduced cells.”
Ahangarani, R. R., Janssens, W., Carlier, V. A., VanderElst, L., VandenDriessche, T., Chuah, M., Jacquemin, M. G., & Saint‐Remy, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.275 · Cited by 19
Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy
Goudy, K., Annoni, A., Naldini, L., & Roncarolo, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00221 · Cited by 19
Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors
Tulalamba, W., Weinmann, J., Pham, Q. H., Andari, J. E., VandenDriessche, T., Chuah, M., & Grimm, D. (2019) · Gene Therapy · doi:10.1038/s41434-019-0106-3 · Cited by 18
Wang, Z., Halbert, C. L., Lee, D., Butts, T. M., Tapscott, S. J., Storb, R. F., & Miller, A. D. (2014) · Gene Therapy · doi:10.1038/gt.2014.4 · Cited by 18
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus
Bing, S. J., Seirup, M., Hoang, T. T., Najera, S. S., Britten, C. N., Warrington, S., Chu, S.-L., & Mazor, R. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01129-8 · Cited by 18
“However, the safety and effectiveness of AAV-vector-mediated gene transfer in humans have been shown to be influenced by immune responses against the AAV capsid, with some cases leading to acute toxicities and loss of efficacy 2,3 .”
The Role of Apoptosis in Immune Hyporesponsiveness Following AAV8 Liver Gene Transfer
Faust, S. M., Bell, P., Zhu, Y., Sanmiguel, J., & Wilson, J. M. (2013) · Molecular Therapy · doi:10.1038/mt.2013.94 · Cited by 17
Developments in the treatment of hemophilia B: focus on emerging gene therapy
Gray, J. T., Cancio, M., Reiss, U. M., Nathwani, A. C., & Davidoff, A. M. (2013) · The Application of Clinical Genetics · doi:10.2147/tacg.s31928 · Cited by 19
Han, J., Zhu, L., Zhang, J., Guo, L., Sun, X., Huang, C., Xu, K., Zhang, Y., Li, W., & Zhou, Q. (2022) · Cell Proliferation · doi:10.1111/cpr.13339 · Cited by 20
“Early clinical trials have found these adverse events are correlated with CD8+ T cell responses against the rAAV capsid.(25,26) These adverse effects appear to a dose-dependent trend.”
BackgroundSemi-mechanistic pharmacodynamic modelling of gene expression and silencing processes
Berraondo, P., González‐Aseguinolaza, G., & Trocóniz, I. F. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.03.013 · Cited by 17
HUGHES, V. A. (2007) · Nature Medicine · doi:10.1038/nm0907-1008 · Cited by 17
Effects of immunosuppression on circulating adeno-associated virus capsid-specific T cells in humans
Parzych, E. M., Li, H., Yin, X., Liu, Q., Wu, T.-L., Podsakoff, G. M., High, K. A., Levine, M. H., & Ertl, H. C. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.246 · Cited by 16
“In humans, on the other hand, AAV-mediated gene transfer is followed by an expansion of AAV capsid-specific T cells and a loss of transgene product expression (Manno et al. , 2006; Mingozzi et al. , 2007, 2009).”
Self-citationAalbers, C. J., Broekstra, N., van Geldorp, M., Kramer, E., Ramiro, S., Tak, P. P., Vervoordeldonk, M. J., & Finn, J. D. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.036 · Cited by 16
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Duan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
The HLA class-II immunopeptidomes of AAV capsids proteins
Brito-Sierra, C. A., Lannan, M. B., Siegel, R. W., & Malherbe, L. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067399 · Cited by 17
“Circulating capsid-specific CD4+ and CD8+ T cells are common among adults (9) and pose a risk when re-dosing because activated CD8+ cells can lyse transduced cells and lead to a reduction of the therapeutic gene (8–10).”
BackgroundMeierrieks, F., Weltken, A., Pflanz, K. B., Pickl, A., Graf, B., & Wolff, M. W. (2024) · Biotechnology Journal · doi:10.1002/biot.202400430 · Cited by 16
“In addition, Mingozzi et al. reported anti-capsid T-cell responses following ocular administration of AAV2 [31].”
Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
de Castro, M. J., del Toro, M., Giugliani, R., & Couce, M. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179200 · Cited by 17
FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
Himeda, C. L., & Jones, P. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060865 · Cited by 21
Margaritis, P., Roy, E., Faella, A., Downey, H. D., Ivanciu, L., Pavani, G., Zhou, S., Bunte, R. M., & High, K. A. (2011) · Blood · doi:10.1182/blood-2010-09-309732 · Cited by 17
Self-citationKumar, S. R. P., Xie, J., Hu, S., Ko, J., Huang, Q., Brown, H. C., Srivastava, A., Markusic, D. M., Doering, C. B., Spencer, H. T., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.001 · Cited by 16
AAV5-mediated gene transfer to the parotid glands of non-human primates
Voutetakis, A., Zheng, C., Cotrim, A. P., Mineshiba, F., Afione, S. A., Roescher, N., Swaim, W. D., Metzger, M. E., Eckhaus, M., Donahue, R. E., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.123 · Cited by 16
High, K. A., & Skinner, M. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.203 · Cited by 16
Self-citationOur journey to successful gene therapy for hemophilia B
Nathwani, A. C., Nienhuis, A. W., & Davidoff, A. M. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2540 · Cited by 15
“At around this time, unexpected results were emerging out of the second gene therapy trial, which entailed a bolus infusion of AAV2 vector containing a strong liver-specific FIX expression cassette into the hepatic artery of patients with severe hemophilia B.”
InfluentialHahn, P. A., & Martins, M. A. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100316 · Cited by 15
Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 17
Gene therapy: therapeutic applications and relevance to pathology
Both, G. W., Alexander, I. E., Fletcher, S., Nicolson, T. J., Rasko, J. E. J., Wilton, S. D., & Symonds, G. P. (2011) · Pathology · doi:10.1097/pat.0b013e32834b1dad · Cited by 17
“Expansion and contraction of this CD8þ capsidspecific T cell population coincided with the rise and fall of serum aminotransferases in a subsequent test subject.(117) Memory T cells will be present in most human populations because the majority of humans are naturally exposed to the AAV-2 serotype early in life.”
BackgroundSelf-citationZou, P. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00555 · Cited by 15
Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?
Herzog, R. W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.96 · Cited by 17
Lambeck, A. J. A., Nijman, H. W., Hoogeboom, B. N., Regts, J., de Mare, A., Wilschut, J., & Daemen, T. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.033 · Cited by 15
Multilineage transduction of resident lung cells in vivo by AAV2/8 for α1-antitrypsin gene therapy
Payne, J. G., Takahashi, A., Higgins, M. I., Porter, E. L., Suki, B., Balazs, A. B., & Wilson, A. A. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.42 · Cited by 15
Wen, Y., Wang, X., Cahya, S., Anderson, P., Velasquez, C., Torres, C., Ferrante, A., & Kaliyaperumal, A. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113147 · Cited by 15
O’Reilly, M., Kohn, D. B., Bartlett, J. S., Benson, J. M., Brooks, P. J., Byrne, B. J., Camozzi, C. R., Cornetta, K. G., Crystal, R. G., Fong, Y., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.064 · Cited by 15
“Data indicated that the loss of transgene expression was due to the destruction of the transduced liver cells by AAV capsid– specific CD8 + T cells (Mingozzi et al., 2007).”
BackgroundSelf-citationXicluna, R., Avenel, A., Vandamme, C., Devaux, M., Jaulin, N., Couzinié, C., Duff, J. L., Charrier, A., Guilbaud, M., Adjali, O., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.225 · Cited by 14
Thakur, G., Mink, S. R., Garcia, A. J., Bak, H., & Tustian, A. D. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101441 · Cited by 14
Xicluna, R., Schwalie, P. C., Bell, E., von Tell, D., Steiner, G., Seeger, E., Heeren, J. J. F., Turksma, A. W., Pouw, R. B., Schwandt, T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101551 · Cited by 16
Gene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 15
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
“44,45 Capsid-specific T cells are also found in the blood of patients treated with retinal gene therapy, but it is unclear whether they enter the eye and contribute to the elimination of transduced cells.”
Haemophilia, the journey in search of a cure. 1960–2020
Nathwani, A. C., & Tuddenham, E. G. D. (2020) · British Journal of Haematology · doi:10.1111/bjh.17155 · Cited by 15
“Further immunological studies led to the hypothesis that the decline in FIX expression and the transaminitis were likely due to memory AAV2 capsid-specific cytotoxic T cells directed against the transduced hepatocytes, which was thought to be a legacy of prior exposure to wild-type AAV2.”
ResultGong, H., Yuan, N., Shen, Z., Tang, C., Shipp, S. D., Liling, Q., Lu, Y., Andolina, I. M., Zhang, S., Wu, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102685 · Cited by 14
Kistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
Duzenli, O. F., & Aslanidi, G. (2025) · Biomedicines · doi:10.3390/biomedicines13020361 · Cited by 13
Gernoux, G., Guilbaud, M., Devaux, M., Journou, M., Pichard, V., Jaulin, N., Léger, A., Duff, J. L., Deschamps, J., Guiner, C. L., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.003 · Cited by 14
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
Brown, D. W., Beatty, P. H., & Lewis, J. D. (2022) · Cancers · doi:10.3390/cancers14215176 · Cited by 13
Li, Z., Jayandharan, G. R., Aslanidi, G., Zolotukhin, S., Herzog, R. W., & Srivastava, A. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-008 · Cited by 16
“FIX expression in the hemophilia B clinical trial was due to the CD8+ T cell response to input capsids in patients who received high vector doses [25,30,69].”
BackgroundGenetic Modification of Donor Hepatocytes Improves Therapeutic Efficacy for Hemophilia B in Mice
Wu, Y., Kao, C., Huang, Y., Yu, I., Lee, M., Lai, H., Lee, P., Lin, C., & Lin, S. (2010) · Cell Transplantation · doi:10.3727/096368910x503398 · Cited by 14
Current and Future Treatments for Lysosomal Storage Disorders
Rastall, D. P. W., & Amalfitano, A. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0481-2 · Cited by 15
Yu, Z., Zhou, S., Luo, N., Ho, C. Y., Chen, M., & Chen, H. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.009 · Cited by 14
Helper-dependent adenoviral vectors
Brunetti‐Pierri, N., & Ng, P. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0165-8_13 · Cited by 14
Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery
Carneiro, A. D., Lee, H., Lin, L. W., van Haasteren, J., & Schaffer, D. V. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.169 · Cited by 13
“34 Consequently, in a phase I trial for hemophilia, both liver enzyme elevation and AAV capsid-mediated T cell responses in peripheral blood were detected, but transient glucocorticoid administration alleviated these responses and preserved Factor IX expression.”
Gene Transfer in the Liver Using Recombinant Adeno‐Associated Virus
Ahmed, S. S., Li, J., Godwin, J., Gao, G., & Li, Z. (2013) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc14d06s29 · Cited by 13
Lee, Y. S., Lee, J., Fang, K., Gee, G. V., Rogers, B. J., McNally, D., & Yoon, S. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124206 · Cited by 15
Lekstrom-Himes, J. A., Brooks, P. J., Koeberl, D. D., Brower, A., Goldenberg, A. J., Green, R. C., Morris, J. A., Orsini, J. J., Yu, T. W., & Augustine, E. F. (2023) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32031 · Cited by 14
Barriers in Heart Failure Gene Therapy and Approaches to Overcome Them
Ravichandran, A. J., Romeo, F. J., Mazurek, R., & Ishikawa, K. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.02.011 · Cited by 12
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.